

Dr. Alisa Pedrana, PhD Burnet Institute, Melbourne Australia

M Traeger, A Pedrana, B Draper, J Asselin, J Doyle, C El-Hayek, J Howell, A Thompson, N Roth, BK Tee, J Willcox, Hellard M, Stoové M



Disclosures





- Our research program receives funding for investigator initiated research grants from National Health and Medical Research Council, Gilead Sciences, Abbvie, Merck and BMS.
- Alisa Pedrana receives travel support from Gilead Sciences.

Burnet Institute

Background

- Hepatitis C direct-acting antiviral treatments (DAAs) were listed for public subsidy in Australia in March 2016
- National hepatitis C elimination strategies focus on testing and treatment uptake among people who inject drugs and HIV-positive co-infected gay and bisexual men (GBM)
- Reaching high levels of treatment uptake among HIV-HCV co-infected GBM will play a vital role in eliminating hepatitis C
- We describe testing and treatment outcomes among HIV/HCV co-infected GBM following the introduction of direct-acting antivirals in Australia





Conclusions



- Findings suggest additional effort needed to increase HCV testing and treatment uptake among HIV+ GBM in clinical care
- High retention in care among patients treated for HCV highlights opportunity for micro-elimination in clinical setting
- Continued monitoring for HCV reinfection will be critical in eliminating hepatitis C among HIV-positive GBM

Burnet Institute

Acknowledgements

Implementing ACCESS sites and staff and also the Kirby Institute and Australian National Reference laboratory as key partners.

Funding support for this work was received from the Australian Government Department of Health, National Health and Medical Research Council and Gilead Sciences.

Special thanks to Michael Traeger and Jason Asselin from the ACCESS Team

4